

MROQC Prostate Tip Sheet

Eligible	Ineligible
<ul style="list-style-type: none"> • Patients without email can be included if patient <u>agrees to fill out paper surveys</u>. • Adenocarcinoma • Curative intent with radiotherapy to at least the prostate or prostate bed (<i>includes adjuvant or salvage RT with or without hormone therapy</i>). • Localized disease ± regional tissues/nodal mets (regional lymph node mets included: <i>Obturator, internal iliac, external iliac, common iliac nodes</i>). 	<ul style="list-style-type: none"> • Patient REFUSED to complete surveys (please make patient alert). • Neuroendocrine or Small Cell cancer (<i>confirmed by pathology</i>). • Mets to bone. • Mets to nodes ABOVE common iliacs (e.g., <i>para-aortic, mediastinal, hilar, supraclavicular</i>) • Mets to viscera (e.g., <i>lung, liver, brain</i>) • Prior pelvic radiation as part of a different course (<i>patients treated with combination EBRT/Brachy at the same institution are ELIGIBLE</i>) • Second active cancer CURRENTLY receiving therapy or PLANNED therapy within the next 12 months. • Prior focal therapy (<i>cryo, HIFU, focal laser ablation</i>).

Timeline of PATIENT SURVEYS

New Start Teach (or 1 st OTV if missed)	3-9 Months* After RT	9-15 Months* After RT	21-27 Months* After RT	57-63 Months* After RT
P1 (Intact Prostate) P2 (Prostatectomy)	P5	P5	P5	P5

* Follow up appointments may vary.